The Effect of Postoperative Blood Transfusions on Muscle Tissue Oxygenation after Hip and Knee Arthroplasty.
IRB Number: 2012-034
inactiveNovember 22, 2011
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Principal Investigator
- Stavros G. Memtsoudis, MD, PhD
Co-Investigators
- Michael Nurok, MBChB, PhD
- Sean Garvin, MD
- Friedrich Boettner, MD
- Matthias Walz, MD
- Yan Ma, PhD
- Thomas Danninger, MD
- Carey Ford
- Isabelle Kao
- Daniel Yoo, MB
Summary
Inclusion/Exclusion Criteria
Inclusion Criteria:
All patients undergoing primary total knee or hip arthroplasty with a hematocrit of 38 or less on preoperative testing. This will increase the likelihood that patients will require postoperative blood transfusions.
Exclusion Criteria:
Patients with a hematocrit of greater than 38 at pre-operative testing and vulnerable populations such as minors, pregnant women, employees, prisoners, and the mental disabled.
Patients taking vasopressors and/or inotropic agents post-operatively
Contact Information
Stavros G. Memtsoudis, MD
memtsoudiss@hss.edu
212.606.1206